For the quarter ending 2025-09-30, NERV had -$2,961,264 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total expenses | 10,121,381 | - |
| Loss from operations | -10,121,381 | - |
| Foreign exchange losses | -35,732 | - |
| Investment income | 401,599 | - |
| Net (loss) income | -2,743,954 | -7,011,560 |
| Depreciation and amortization | 1,361 | 2,721 |
| Amortization of capitalized software | - | 0 |
| Non-cash interest expense associated with the sale of future royalties | - | 0 |
| Stock-based compensation expense | 272,897 | 595,447 |
| Prepaid expenses and other current assets | 433,918 | -607,280 |
| Accounts payable | -72,739 | -711,045 |
| Accrued expenses and other current liabilities | 60,255 | 403,059 |
| Net cash used in operating activities | -2,916,098 | -6,114,098 |
| Net cash provided by investing activities | 0 | 0 |
| Costs paid in connection with private placements | 45,166 | - |
| Net cash (used in) provided by financing activities | -45,166 | 0 |
| Net decrease in cash, cash equivalents and restricted cash | -2,961,264 | -6,114,098 |
| Cash and cash equivalents at beginning of period | 21,462,008 | - |
| Cash and cash equivalents at end of period | 12,386,646 | - |
Minerva Neurosciences, Inc. (NERV)
Minerva Neurosciences, Inc. (NERV)